دورية أكاديمية
Joint association of hyperuricemia and chronic kidney disease with mortality in patients with chronic heart failure
| العنوان: | Joint association of hyperuricemia and chronic kidney disease with mortality in patients with chronic heart failure |
|---|---|
| المؤلفون: | Chi Wang, Hebin Che, You Zhou, Ruiqing Wang, Di Zhu, Liting Cheng, Chongyou Rao, Qin Zhong, Zongren Li, Yongjie Duan, Jiayu Xu, Wei Dong, Yongyi Bai, Kunlun He |
| المصدر: | Frontiers in Endocrinology, Vol 14 (2023) |
| بيانات النشر: | Frontiers Media S.A., 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Diseases of the endocrine glands. Clinical endocrinology |
| مصطلحات موضوعية: | uric acid, chronic kidney disease, heart failure, mortality risk, cohort study, Diseases of the endocrine glands. Clinical endocrinology, RC648-665 |
| الوصف: | BackgroundThe joint association of hyperuricemia and chronic kidney disease (CKD) with mortality in patients with chronic heart failure (CHF) is not conclusive.MethodsThis retrospective cohort study was conducted in Chinese People's Liberation Army General Hospital, Beijing, China. We included 9,367 patients with CHF, who were hospitalized between January 2011 and June 2019. The definitions of hyperuricemia and CKD were based on laboratory test, medication use, and medical record. We categorized patients with CHF into 4 groups according to the absence (-) or presence (+) of hyperuricemia and CKD. The primary outcomes included in-hospital mortality and long-term mortality. We used multivariate logistic regression and Cox proportional hazards regression to estimate the mortality risk according to the hyperuricemia/CKD groups.ResultsWe identified 275 cases of in-hospital mortality and 2,883 cases of long-term mortality in a mean follow-up of 4.81 years. After adjusting for potential confounders, we found that compared with the hyperuricemia-/CKD- group, the risks of in-hospital mortality were higher in the hyperuricemia+/CKD- group (odds ratio [OR], 95% confidence interval [CI]: 1.58 [1.01-2.46]), hyperuricemia-/CKD+ group (OR, 95% CI: 1.67 [1.10-2.55]), and hyperuricemia+/CKD+ group (OR, 95% CI: 2.12 [1.46-3.08]). Similar results were also found in long-term mortality analysis. Compared with the hyperuricemia-/CKD- group, the adjusted hazard ratios and 95% CI for long-term mortality were 1.25 (1.11-1.41) for hyperuricemia+/CKD- group, 1.37 (1.22-1.53) for hyperuricemia-/CKD+ group, and 1.59 (1.43-1.76) for hyperuricemia+/CKD+ group. The results remained robust in the sensitivity analysis.ConclusionsHyperuricemia and CKD, both individually and cumulatively, are associated with increased mortality risk in patients with CHF. These results highlighted the importance of the combined control of hyperuricemia and CKD in the management of heart failure. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1664-2392 49742043 |
| Relation: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1131566/full; https://doaj.org/toc/1664-2392 |
| DOI: | 10.3389/fendo.2023.1131566 |
| URL الوصول: | https://doaj.org/article/49742043626e4146bec3a98c70336ee1 |
| رقم الأكسشن: | edsdoj.49742043626e4146bec3a98c70336ee1 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 16642392 49742043 |
|---|---|
| DOI: | 10.3389/fendo.2023.1131566 |